Recently, China government found first case of Middle East Respiratory Syndrome (MERS). The reporter from famous Therapeutic antibody engineering service supplier chempartner.com learned from the Chinese Academy of Sciences Institute of Biology that China has developed a plurality of therapeutic antibodies drugs but most of those drugs are at the laboratory level and need the next clinical studies.
Middle East Respiratory Syndrome (MERS) is one kind of newly viral respiratory disease which caused by the novel coronavirus and the virus was first discovered in 2012 in Saudi Arabia. According to the assistant researcher Wu Ying from Chinese Academy of Sciences Institute of Biology, as early as in 2013, Chinese Academy of Sciences research team began to study MERS antibody.
"Following with the outbreak of MERS in the Middle East, our entire research team began to study the mechanism in this regard and already got very deeply result. Our result already published in the international 'Nature' journal," said Wu Jing.
Ying Wu also revealed that their group already developed appropriate Epigenetics in the mouse model and the result is quite substantial. It is understood that China has already developed more than one therapeutic antibody and peptide drugs which all at the laboratory testing level and the next step should be the clinical research.
For more information about the Therapeutic antibody engineering, please visit website www.chempartner.com
About Chempartner.com
We are proud to introduce to you ChemPartner, an evolution from the pure chemistry service provider that originated 12 years ago, into the full-service LifeScience CRO with deep and extensive pharmaceutical research understanding at all levels.
Media ContactCompany Name: Chempartner.com
Email:Send Email
Phone: +86 21 5132 0088
Country: United States
Website: www.chempartner.com
